Procedure with SR18662 drastically reduces advancement and proliferation of CRC cells. SR18662 exhibits enhanced efficacy in lowering viability of multiple CRC mobile lines. Stream cytometry analysis following SR18662 treatment displays a rise in cells captured in either S or G2/M phases of the mobile cycle and a substantial boost in the quantity o